[Reversible posterior encephalopathy syndrome and cardiomyopathy after bevacizumab therapy]

Authors :: Frantzen, Lea
Rondeau-Lutz, Murielle
Mosquera, Felipe
Martinez, Camille
Labani, Aissam
Weber, Jean-Christophe
Institut de recherches interdisciplinaires sur les sciences et la technologie (IRIST)
Université de Strasbourg (UNISTRA)
Source :: La Revue De Médecine Interne, La Revue De Médecine Interne, Elsevier, 2016, 37 (1), ⟨10.1016/j.revmed.2015.04.011⟩
Publication Year :: 2016
Publisher :: HAL CCSD, 2016.
Abstract: National audience; Bevacizumab is an antibody directed against VEGF-A. It is approved for the treatment of many cancer diseases. Its side effects are currently not well known by physicians.

Language :: French
ISSN :: 02488663 and 17683122
Database :: OpenAIRE
Journal :: La Revue De Médecine Interne, La Revue De Médecine Interne, Elsevier, 2016, 37 (1), ⟨10.1016/j.revmed.2015.04.011⟩
Accession number :: edsair.dedup.wf.001..2dbe3010ad5fadce3f40877c654f223b
Full Text :: https://doi.org/10.1016/j.revmed.2015.04.011⟩

Full Text Access

Tools